Mary Kay Fenton

Mary Kay Fenton is a seasoned financial executive with extensive experience in leadership roles across various biotechnology and pharmaceutical companies. Currently serving as Chief Financial Officer at Cullinan Therapeutics since April 2024, Fenton previously held significant positions such as President and Interim Chief Executive Officer at Talaris Therapeutics and Chief Financial Officer at Semma Therapeutics. Fenton has also contributed to Oncorus as a Board Director and Audit Committee Chair, and has held the Vice President of Strategic Operations role at Vertex Pharmaceuticals. With a strong background in capital fundraising, Fenton has raised over $1 billion through public and private markets during tenure as EVP & Chief Financial Officer at Achillion Pharmaceuticals. Fenton's career began with PricewaterhouseCoopers, where leadership roles in audit and financial consulting helped establish a prominent bioscience practice. In addition to a robust professional trajectory, Fenton holds degrees from the College of the Holy Cross and the University of Connecticut, along with completion of the BIO Boardroom Ready Program at The George Washington University.